Drugs Containing Excipient (Inactive Ingredient) MALTOL

Branded drugs containing MALTOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lohxa	VIMPAT	lacosamide	70166-617	MALTOL

Generic drugs containing MALTOL excipient

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	diphenoxylate hydrochloride and atropine sulfate	0054-3194	MALTOL
Atlantic Biologicals Corps	diphenoxylate hydrochloride and atropine sulfate	17856-3194	MALTOL
Atlantic Biologicals Corps	prednisone	17856-3722	MALTOL
Carilion Materials Management	prednisone	68151-0820	MALTOL
Lohxa	lacosamide	70166-617	MALTOL
Lohxa	diphenoxylate hydrochloride and atropine sulfate	70166-630	MALTOL

Maltol Excipient Market Dynamics and Financial Trajectory

Last updated: September 24, 2026

Maltol is a low-cost flavoring and taste-masking ingredient used in oral pharmaceutical and nutraceutical formulations. Its commercial position is driven less by pharmaceutical exclusivity than by demand from food, beverages, cosmetics, and supplements. Pharmaceutical use is strategically relevant but generally represents a smaller share of total maltol consumption.

Maltol has the chemical name 3-hydroxy-2-methyl-4-pyrone and CAS number 118-71-8. It is distinct from ethyl maltol, which has CAS number 4940-11-8 and stronger flavor intensity. Maltol is listed as flavoring substance E636 in the European Union, while ethyl maltol is E637.[1]

The financial trajectory for maltol is likely to remain tied to volume growth, purity requirements, regional manufacturing costs, and formulation demand rather than patent-protected pricing. Public companies generally do not disclose maltol revenue separately, and publicly available market estimates often combine maltol with ethyl maltol, flavor enhancers, or broader pharmaceutical excipient categories.

What is maltol used for in pharmaceutical formulations?

Maltol is used primarily as a flavoring and taste-masking excipient in oral dosage forms.

Common pharmaceutical applications

Application	Maltol’s role	Commercial relevance
Oral liquids	Masks bitterness and improves palatability	High relevance for pediatric and geriatric medicines
Syrups and suspensions	Provides a sweet, caramel-like flavor profile	Supports repeat dosing and adherence
Chewable tablets	Reduces unpleasant active-ingredient taste	Relevant to over-the-counter and pediatric products
Orally disintegrating tablets	Improves mouthfeel and residual taste	Supports premium dosage-form development
Sachets and powders	Improves flavor after reconstitution	Used in supplements and prescription products
Nutraceuticals	Masks mineral, botanical, and amino-acid notes	Expands demand beyond pharmaceutical products

Maltol is not a primary filler, binder, disintegrant, lubricant, or coating polymer. Its value is functional and sensory. It can improve patient acceptability, but it does not materially control tablet compression, dissolution, mechanical strength, or release kinetics.

The pharmaceutical opportunity is strongest where the active ingredient has a pronounced bitter, metallic, sulfurous, or mineral taste. Maltol is less attractive in formulations requiring strict low-calorie labeling, very low flavor loadings, or highly neutral sensory profiles.

How large is the maltol excipient market?

No authoritative public source reports a standalone global market size for maltol used as a pharmaceutical excipient. Public estimates usually aggregate one or more of the following:

• Maltol and ethyl maltol
• Flavoring agents
• Taste-masking excipients
• Pharmaceutical excipients
• Food-grade flavor enhancers
• Specialty chemicals

This aggregation materially affects reported market values. A market estimate covering all maltol applications should not be treated as pharmaceutical-excipient revenue.

The economically relevant market structure is best understood as a layered market:

Market layer	Relative scale	Main demand drivers
Food and beverage flavoring	Largest	Processed foods, beverages, confectionery
Nutraceuticals and supplements	Medium	Mineral products, powders, chewables
Cosmetics and personal care	Smaller	Fragrance and sensory modification
Pharmaceutical excipients	Smaller but higher specification	Pediatric liquids, taste-masked tablets, oral powders
Research and specialty use	Limited	Analytical, formulation, and development applications

Maltol’s pharmaceutical share is likely to have a higher average selling price than bulk food-grade material when the customer requires pharmaceutical documentation, tighter impurity controls, traceability, change-control support, and audited manufacturing.

What is driving maltol market growth?

Growth is being supported by oral formulation complexity, pediatric medicines, nutraceutical expansion, and demand for more acceptable dosage forms.

Pediatric and geriatric formulations

Liquid medicines and chewable products require sensory optimization because adherence is directly affected by taste. Maltol can be used in combination with sweeteners, fruit flavors, acids, and other masking agents.

Pediatric demand is particularly relevant because a formulation that is chemically acceptable may fail commercially if children refuse repeated doses. This creates demand for flavor systems that work at low concentrations and remain stable during storage.

Taste masking for active pharmaceutical ingredients

Maltol can complement polymer coatings, ion-exchange resins, cyclodextrins, lipid barriers, and sweetener systems. It is generally more valuable as part of a formulation platform than as a standalone taste-masking solution.

A formulation developer may use maltol to improve flavor after a separate process reduces the active ingredient’s exposure in the mouth. This creates a competitive position for maltol against natural flavors, artificial flavors, sweeteners, and proprietary taste-masking systems.

Nutraceutical expansion

Maltol is relevant to iron, zinc, magnesium, amino-acid, botanical, and protein products. These products often have metallic, earthy, bitter, or astringent sensory characteristics. Nutraceutical manufacturers also tend to launch products in powders, gummies, chewables, and oral liquids, all of which create flavoring demand.

Clean-label and regulatory pressure

Food and supplement companies are placing greater emphasis on ingredient identity, source documentation, and labeling. This can favor suppliers with consistent manufacturing, regional regulatory files, and reliable documentation. It can also increase qualification costs for smaller suppliers.

What factors are constraining maltol pricing?

Maltol is exposed to commodity-style pricing pressure because the molecule is relatively simple, widely available, and not protected by a meaningful active patent estate.

Manufacturing and raw-material economics

Pricing is influenced by:

• Availability and cost of chemical intermediates
• Energy consumption
• Chinese manufacturing capacity
• Environmental controls
• Solvent and waste-treatment costs
• Batch size and plant utilization
• Packaging and transport expenses
• Pharmaceutical-grade documentation

Food-grade buyers can often qualify multiple suppliers. Pharmaceutical customers have fewer practical options because supplier changes can require technical assessment, stability review, quality agreements, and regulatory documentation.

Grade segmentation

The principal commercial distinction is not the molecule itself but the grade and service package.

Grade	Typical customer	Main qualification criteria
Food grade	Flavor houses and food manufacturers	Identity, purity, sensory performance, food compliance
Pharmaceutical-suitable	Drug and supplement manufacturers	GMP controls, impurity profile, traceability
Compendial or customer-specific	Regulated pharmaceutical customers	Monographs, validated methods, change control
High-purity specialty	Research and premium formulations	Tight specifications and small-batch reliability

A supplier with food-grade material may not be interchangeable with a supplier qualified for pharmaceutical production. The price premium depends on documentation, audit history, testing, and supply continuity rather than molecular differentiation.

Which companies supply maltol and related flavoring ingredients?

Maltol supply is fragmented across flavor houses, specialty chemical companies, and Asian manufacturers. Public disclosures do not consistently separate maltol sales from broader flavoring or aroma-chemical revenue.

The competitive landscape includes:

1. Large flavor and fragrance companies that formulate maltol into broader flavor systems.
2. Specialty chemical producers that sell maltol as a discrete ingredient.
3. Chinese manufacturers that compete on cost and volume.
4. Regional distributors that provide regulatory documentation and local inventory.
5. Contract manufacturers that supply customer-specific blends for pharmaceutical and nutraceutical products.

Large flavor companies may have stronger customer relationships and application laboratories, while lower-cost producers may compete more effectively for standardized bulk material. Pharmaceutical buyers often evaluate both sources because the lowest unit price does not necessarily produce the lowest total cost after qualification, testing, and supply-risk assessment.

What is the regulatory status of maltol?

Maltol is regulated primarily as a flavoring substance rather than as an active pharmaceutical ingredient.

United States

The U.S. Food and Drug Administration regulates flavoring substances under the Federal Food, Drug, and Cosmetic Act and related regulations. Maltol is recognized in U.S. flavoring frameworks, including the provisions covering flavoring substances used in food.[2] FEMA identifies maltol as FEMA No. 2656.[3]

For pharmaceutical use, the relevant question is whether the proposed amount, route, dosage form, and patient population are acceptable under the applicable formulation and regulatory framework. A food-use authorization does not automatically establish unrestricted use in every pharmaceutical dosage form.

European Union

Maltol is identified as E636 under the European Union flavoring framework. Ethyl maltol is separately identified as E637.[1] A pharmaceutical sponsor must still assess excipient suitability, quality, toxicology, specifications, and route-specific use.

JECFA

The Joint FAO/WHO Expert Committee on Food Additives has evaluated maltol as a flavoring agent. JECFA assessments are relevant to international food-safety acceptance but do not replace pharmaceutical qualification.[4]

Pharmaceutical excipient documentation

A regulated pharmaceutical customer typically expects:

• Certificate of analysis
• Residual-solvent data
• Elemental-impurity assessment
• Microbiological limits
• Allergen and GMO statements where applicable
• Nitrosamine-risk assessment where relevant
• TSE/BSE statements
• Manufacturing-site information
• Change-control commitments
• Stability and retest data
• Supply-chain traceability

What patents protect maltol as a pharmaceutical excipient?

Maltol itself is not a strong current patent asset. The core molecule is old, widely known, and available from multiple commercial sources. Patent value is more likely to arise from a specific formulation, delivery system, manufacturing process, or combination.

Potentially relevant patent categories

Patent category	Potential protection	Commercial strength
Maltol composition claims	Pure maltol or basic mixtures	Generally weak because of prior art
Taste-masking formulations	Maltol combined with an active ingredient or flavor system	Moderate if narrowly defined
Pediatric liquid formulations	Specific concentration, pH, sweetener, and stability profile	Moderate
Orally disintegrating tablets	Maltol combined with excipient architecture	Moderate
Manufacturing processes	Yield, purity, crystallization, or impurity control	Variable
Combination flavor systems	Maltol with acids, sweeteners, or masking agents	Usually narrow
Drug-specific use claims	Use of maltol in a named active formulation	Potentially meaningful but limited

Patent risk should be assessed at the finished-product level. A maltol supplier generally does not create freedom-to-operate risk merely by selling a commodity excipient. Risk arises when the customer manufactures a dosage form covered by a formulation patent or method-of-use patent.

No Orange Book listing should be assumed for maltol because it is an excipient rather than an approved active pharmaceutical ingredient. The Orange Book framework applies to approved drug products and their listed patents, not to ordinary excipients sold independently.[5]

When does maltol lose exclusivity?

Maltol has no meaningful molecule-level exclusivity period comparable to a new chemical entity. Commercial exclusivity depends on:

• Supplier qualification
• Customer-specific specifications
• Manufacturing know-how
• Regulatory documentation
• Long-term supply agreements
• Formulation patents
• Taste-masking performance data

A drug formulation containing maltol may have patent protection even though maltol itself is unpatented. The relevant expiration date would be the patent covering the formulation or use, not a maltol molecule patent.

Paragraph IV challenges are generally not directed at maltol as an excipient. They arise when a generic applicant challenges patents listed for an approved drug product. Maltol-containing drug products could face Paragraph IV litigation if their patents are listed and the generic product is designed around them, but the excipient would be only one component of the dispute.

What generic entry risks exist for maltol-containing medicines?

Generic entry risk is determined by the finished drug’s active ingredient, formulation, dosage form, and listed patents.

Low-risk scenario for the excipient supplier

A generic manufacturer buys maltol from an alternative supplier and produces a product with a materially different flavor system. The excipient is replaceable, and no maltol-specific patent claim is implicated.

Moderate-risk scenario

The reference product relies on a disclosed taste-masking system that includes maltol, a defined concentration range, and a specific active ingredient. A generic applicant may need to design around the claim or challenge it.

Higher-risk scenario

The reference product has narrow formulation claims covering maltol with a particular pH range, sweetener, stabilizer, or dosage form. The generic applicant may face formulation patent litigation even if maltol itself is freely available.

How strong is the maltol patent estate?

The maltol patent estate is weak at the molecule level and potentially stronger at the product level.

Dimension	Assessment
Core compound protection	Weak or expired
Commodity supply protection	Weak
Manufacturing know-how	Moderate
Pharmaceutical-grade qualification	Moderate commercial barrier
Drug-specific formulation patents	Variable
Taste-masking platform patents	Variable to moderate
Orange Book relevance	Limited
Biosimilar relevance	None for maltol itself

Biosimilar risk is not applicable to maltol. Maltol is a small-molecule excipient, not a biologic drug. Biosimilar competition could affect demand for a biologic product that uses maltol in an oral-support formulation, but that is not a direct maltol market risk.

What is the financial trajectory for maltol suppliers?

The likely financial trajectory is steady volume growth with limited structural pricing power.

Base-case trajectory

Revenue growth is likely to come from:

• Higher use of oral liquids and chewables
• Nutraceutical launches
• Greater demand for taste-masking systems
• Supplier qualification in regulated markets
• Growth in Asian pharmaceutical and supplement production

Margin performance will depend on manufacturing efficiency, plant utilization, raw-material costs, and the ability to sell pharmaceutical-grade documentation rather than commodity material.

Upside factors

An upside scenario would involve stronger adoption in pediatric medicines, orally disintegrating tablets, and premium nutraceutical products. Suppliers that offer application development, flavor optimization, and regulatory support could capture more value than bulk producers.

Downside factors

Downside risks include:

• Substitution by ethyl maltol or other flavor systems
• Use of sucralose, stevia, fruit flavors, or proprietary masking agents
• Chinese overcapacity
• Customer backward integration
• Regulatory limits on flavor use
• Weak pricing discipline among distributors
• Reformulation to remove synthetic flavoring ingredients

The greatest financial risk is commoditization. The greatest commercial opportunity is moving from selling maltol as a raw material to selling a validated taste-masking solution.

How does maltol compare with ethyl maltol?

Attribute	Maltol	Ethyl maltol
CAS number	118-71-8	4940-11-8
EU identifier	E636	E637
Flavor profile	Sweet, caramel-like	Stronger sweet, cotton-candy-like
Relative flavor intensity	Lower	Higher
Typical use	Food, beverages, pharmaceuticals	Food, beverages, confectionery, supplements
Pharmaceutical positioning	Mild flavor modification	Stronger masking at lower concentrations
Substitution risk	Moderate	Moderate
Regulatory treatment	Separate substance	Separate substance

Ethyl maltol may provide stronger sensory impact at lower concentrations, but it can also create a more pronounced flavor profile that is unsuitable for some medicines. Selection depends on the active ingredient, dosage form, target age group, pH, sweetener system, and stability profile.

What manufacturing and intellectual-property barriers affect maltol?

The main barriers are operational rather than patent-based.

A pharmaceutical customer may remain with an incumbent supplier because switching requires:

• New supplier qualification
• Comparative impurity testing
• Analytical-method verification
• Stability assessment
• Regulatory documentation updates
• Batch comparability
• Quality-agreement negotiation
• Revalidation of flavor performance

Manufacturing know-how may provide an advantage in controlling color, odor, particle size, residual solvents, and trace impurities. These attributes can affect both sensory performance and pharmaceutical acceptability.

Geographically, Asian producers are likely to remain important for cost-efficient supply. European and North American suppliers may compete through documentation, regional inventory, audit readiness, and application support. Buyers with global products often qualify at least two manufacturing sources to reduce disruption risk.

Key Takeaways

• Maltol is primarily a flavoring and taste-masking excipient, not a core tablet-processing excipient.
• Food and beverage demand is larger than pharmaceutical demand.
• Pharmaceutical growth is linked to pediatric medicines, oral liquids, chewables, orally disintegrating tablets, and nutraceuticals.
• No reliable public source provides a standalone global revenue figure for pharmaceutical-grade maltol.
• Maltol has weak molecule-level patent protection and no meaningful Orange Book position.
• Formulation and method-of-use patents can protect specific maltol-containing drug products.
• Paragraph IV litigation is relevant to finished drug products, not to maltol as a commodity excipient.
• Biosimilar risk does not apply directly to maltol.
• Financial performance will depend on volume, manufacturing efficiency, qualification barriers, and the ability to sell documentation and formulation services.
• Ethyl maltol is the principal related substitute and has a stronger flavor profile.
• The strongest commercial position is likely held by suppliers that combine maltol production with pharmaceutical-grade quality systems and taste-masking support.

FAQs About Maltol Pharmaceutical Excipient Markets

Is maltol an active pharmaceutical ingredient?

No. Maltol is generally used as a flavoring and taste-masking excipient. It does not provide the principal therapeutic effect in a conventional drug product.

Is maltol listed in the FDA Orange Book?

Maltol is not an Orange Book-listed active drug product. Any relevant patent analysis must focus on a finished drug formulation containing maltol.

Can maltol be replaced by ethyl maltol?

Sometimes. Ethyl maltol has a stronger flavor profile, so substitution requires reformulation, sensory testing, stability testing, and regulatory review.

Does maltol have biosimilar competition?

No. Biosimilar pathways apply to biological drug products, while maltol is a small-molecule excipient.

What is the main investment risk in the maltol market?

The main risk is commodity pricing and supplier substitution. Patent protection is limited, and customers can often qualify alternative sources unless the supplier has differentiated pharmaceutical documentation, quality, or application support.

References

1. European Parliament and Council of the European Union. (2008). Regulation (EC) No. 1334/2008 on flavorings and certain food ingredients with flavoring properties for use in and on foods. Official Journal of the European Union.

2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Section 172.560: Natural and synthetic flavoring substances. U.S. Department of Health and Human Services.

3. Flavor and Extract Manufacturers Association. (2024). FEMA flavor ingredient library: Maltol, FEMA No. 2656. FEMA.

4. Joint FAO/WHO Expert Committee on Food Additives. (2006). Compendium of food additive specifications: Maltol. Food and Agriculture Organization of the United Nations and World Health Organization.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.